SEC Tracker
Get the app

Palisade Bio PALI

Palisade Bio reports Q3 2026 financial results and clinical updates.

Palisade Bio (PALI) filed an 8-K with the SEC on Nov 10, 2026, 4:23 pm ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. $113.6 million in cash and cash equivalents as of September 30, 2026.
  2. First patient dosed in ASCENTRA-UC trial on October 27, 2026.
  3. FDA cleared IND application for ASCENTRA-CD trial in Crohn's disease.
  4. Research and development expenses were $10.6 million for the three months ended September 30, 2026.

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Palisade Bio files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.